1. Kraepelin E. Manic-Depressive Insanity and Paranoia. Edinburgh: E & S Livingstone; 1921.
2. Goodwin F, Jamison K. Manic Depressive Illness. 2nd Edition. New York: Oxford University Press; 2007.
3. Leonhard K. The Classification of Endogenous Psychoses. New York: Irvington; 1957.
4. Woodruff RA, Goodwin DW, Guze SB. Psychiatric Diagnosis. First Edition. New York: Oxford University Press; 1974.
5. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35:773–782.[PubMed]
6. Association AP. Diagnostic and Statistical Manual of Mental Disorders. Third Edition. Washington, DC: American Psychiatric Association; 1980.
7. Shorter E. Before Prozac: The Troubled History of Mood Disorders in Psychiatry. New York: Oxford University Press; 2009.
8. Roth S, Kerr T. The Concept of Neurotic Depression: A Plea for Reinstatement. In: Pichot P, Rein W, editors. The Clinical Approach in Psychiatry. Paris, France: Synthelabo; 1994. pp. 339–368.
9. Ghaemi SN. Taking Disease Seriously: Against "Pragmatic" Nosology. In: Kendler KS, Parnas J, editors. Philosophical Issues in Psychiatry II: Nosology. Oxford: Oxford University Press; 2012. pp. 42–52.
10. Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand Suppl. 1966;194:9–14.[PubMed]
11. Klerman G. Historical Perspectives on Contemporary Schools of Psychopathology. In: Millon Theodore., editor. Contemporary Directions in Psychopathology: Toward the DSM-IV. New York: Guilford Press; 1986. pp. 3–28.
12. Ghaemi SN. On Depression: Diagnosis, Drugs, and Despair in the Modern World. Baltimore: Johns Hopkins University Press; 2013.
13. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry. 1970;126:983–987.[PubMed]
14. Angst J. On the etiology and nosology of endogenous depressive psychoses. A genetic, sociologic, and clinical study. Monogr Gesamtgeb Neurol Psychiatr. 1966;112:1–118.[PubMed]
15. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509–522.[PubMed]
16. Akiskal HS. The Bipolar Spectrum: New Concepts in Classification and Diagnosis. In: Grinspoon L, editor. Psychiatry Update; The American Psychiatric Association Annual Review. Vol. 2. Washington DC: American Psychiatric Press; 1983. pp. 271–292.
17. Koukopulos A, Reginaldi P, Laddomada G, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol. 1980;13:156–167.[PubMed]
18. Koukopoulos A, Tundo A. A mixed depressive syndrome. Clin Neuropharmacol. 1992;15(Suppl 1)(Pt A):626A–627A.[PubMed]
19. Gershon ES, Hamovit J, Guroff JJ, Dibble E, Leckman JF, Sceery W, et al. A family study of schizoaffective, bipolar I, bipolar II, unipolar and normal control probands. Arch Gen Psychiatry. 1982;39:1157–1167.[PubMed]
20. Prien RF, Klett CJ, Caffey EM., Jr Lithium prophylaxis in recurrent affective illness. Am J Psychiatry. 1974;131:198–203.[PubMed]
21. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry. 1996;153:151–162.[PubMed]
22. Manji HK. G proteins: implications for psychiatry. Am J Psychiatry. 1992;149:746–760.[PubMed]
23. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry. 2000;5:578–593.[PubMed]
24. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166:980–991.[PubMed]
25. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65:432–441.[PubMed]
26. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–260.[PubMed]
27. Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am. 1999;22:517–534.[PubMed]
28. Koukopoulos A, Sani G, Koukopoulos AE, Manfredi G, Pacchiarotti I, Girardi P. Melancholia agitata and mixed depression. Acta Psychiatr Scand Suppl. 2007;(433):50–57.[PubMed]
29. Benazzi F. Depressive mixed states: unipolar and bipolar II. Eur Arch Psychiatry Clin Neurosci. 2000;250:249–253.[PubMed]
30. Benazzi F. Depressive mixed state: testing different definitions. Psychiatry Clin Neurosci. 2001;55:647–652.[PubMed]
31. Benazzi F. Depressive mixed state frequency: age/gender effects. Psychiatry Clin Neurosci. 2002;56:537–543.[PubMed]
32. Benazzi F. Mixed depression: a clinical marker of bipolar-II disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:267–274.[PubMed]
33. Benazzi F. Mixed depression and the dimensional view of mood disorders. Psychopathology. 2007;40:431–439.[PubMed]
34. Benazzi F, Akiskal HS. Delineating bipolar II mixed states in the Ravenna-San Diego collaborative study: the relative prevalence and diagnostic significance of hypomanic features during major depressive episodes. J Affect Disord. 2001;67:115–122.[PubMed]
35. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 1998;50:143–151.[PubMed]
36. Angst J. The bipolar spectrum. Br J Psychiatry. 2007;190:189–191.[PubMed]
37. Angst J, Azorin JM, Bowden CL, Perugi G, Vieta E, Gamma A, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE Study. Arch Gen Psychiatry. 2011;68:791–798.[PubMed]
38. Angst J, Gamma A, Bowden CL, Azorin JM, Perugi G, Vieta E, et al. Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes. Eur Arch Psychiatry Clin Neurosci. 2012;262:3–11.[PubMed]
39. Ghaemi SN, Ko JY, Goodwin FK. "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry. 2002;47:125–134.[PubMed]
40. Smith DJ, Harrison N, Muir W, Blackwood DH. The high prevalence of bipolar spectrum disorders in young adults with recurrent depression: toward an innovative diagnostic framework. J Affect Disord. 2005;84:167–178.[PubMed]
41. Rybakowski JK, Suwalska A, Lojko D, Rymaszewska J, Kiejna A. Types of depression more frequent in bipolar than in unipolar affective illness: results of the Polish DEP-BI study. Psychopathology. 2007;40:153–158.[PubMed]
42. Koukopoulos A, Ghaemi SN. The primacy of mania: a reconsideration of mood disorders. Eur Psychiatry. 2009;24:125–134.[PubMed]
43. Gunderson J. Borderline Personality Disorder. Washington DC: American Psychiatric Press; 1984.
44. Kendler KS, Prescott C. Genes, Environment, and Psychopathology. New York: Guilford Press; 2006.
45. Bienvenu OJ, Davydow DS, Kendler KS. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence. Psychol Med. 2011;41:33–40.[PubMed]
46. Cassano GB, Rucci P, Benvenuti A, Miniati M, Calugi S, Maggi L, et al. The role of psychomotor activation in discriminating unipolar from bipolar disorders: a classification-tree analysis. J Clin Psychiatry. 2012;73:22–28.[PubMed]
47. Benazzi F. Borderline personality-bipolar spectrum relationship. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:68–74.[PubMed]
48. Phelps J, Ghaemi SN. The mistaken claim of bipolar 'overdiagnosis': solving the false positives problem for DSM-5/ICD-11. Acta Psychiatr Scand. 2012;126:395–401.[PubMed]
49. Zanarini MC. Childhood experiences associated with the development of borderline personality disorder. Psychiatr Clin North Am. 2000;23:89–101.[PubMed]
50. Nock MK, Kessler RC. Prevalence of and risk factors for suicide attempts versus suicide gestures: analysis of the National Comorbidity Survey. J Abnorm Psychol. 2006;115:616–623.[PubMed]
51. Akiskal HS. Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatr Scand. 2004;110:401–407.[PubMed]
52. Beumont PJ. Phenomenology and the history of psychiatry. Aust N Z J Psychiatry. 1992;26:532–545.[PubMed]
53. Decker HS. The psychiatric works of Emil Kraepelin: a many-faceted story of modern medicine. J Hist Neurosci. 2004;13:248–276.[PubMed]
54. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003;5:421–433.[PubMed]
55. Berk M, Dodd S. Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression? Med Hypotheses. 2005;65:39–43.[PubMed]
56. Jacobsen FM. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J Clin Psychiatry. 1993;54:229–234.[PubMed]
57. Ghaemi SN, Bauer M, Cassidy F, Malhi GS, Mitchell P, Phelps J, et al. Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report. Bipolar Disord. 2008;10:117–128.[PubMed]
58. Association AP. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
59. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126.[PMC free article][PubMed]
60. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748–751.[PubMed]
Citation: Patel V (2017) Talking sensibly about depression. PLoS Med 14(4): e1002257. https://doi.org/10.1371/journal.pmed.1002257
Published: April 4, 2017
Copyright: © 2017 Vikram Patel. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: VP is supported by a Wellcome Trust Principal Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: VP is a member of the PLOS Medicine Editorial Board.
Abbreviations: HAP, Healthy Activity Program; PHQ-9, Patient Health Questionnaire-9
Provenance: Commissioned, externally peer-reviewed.
The past 12 months have been a momentous year for global mental health, the discipline of global health concerned with reducing the burden of mental ill-health and inequalities within and between nations. The World Bank and WHO jointly hosted the “Out of the Shadows” summit in Washington in April 2016 to highlight mental health as a global “development” priority, signifying a notable shift in emphasis from a narrower health focus to development more broadly. Twelve months later, the WHO celebrates its annual World Health Day in April 2017 on the theme of depression. This is a very timely (indeed, greatly overdue) recognition, for not only is depression the leading mental health—related cause of the global burden of disease but also because, despite the reams of evidence on how the suffering associated with this condition can be mitigated, vast proportions of people globally do not benefit from these interventions . Even in the relatively better-resourced, middle-income countries such as India and China, up to 90% of patients with depression report not having sought or received any care for their symptoms .
The slogan for World Health Day is “let’s talk,” emphasizing the central role of disclosure “as a vital component of recovery” by targeting the stigma surrounding mental illness, which acts as a barrier to people with depression seeking help. Significantly, the WHO campaign recommends that talking can involve a wide range of potential listeners, from family members and friends to health professionals, as well as encouraging open discussions about this condition in settings such as schools, the workplace, and in the media, “ultimately leading to more people seeking help.” I emphatically support the notion that seeking help must include both professional and nonprofessional actors. Despite this pragmatic recommendation, there is still little tangible action by governments and health systems to implement the evidence on effective interventions, and this is, at least in part, because of dissonant perspectives about the very nature of this condition. Indeed, some commentators view the discourse on the global burden of depression and the treatment gap as a culturally insensitive plot to export a failed psychiatric model to unsuspecting developing countries and a ploy to expand markets for pharmaceutical companies .
If we are to talk sensibly about depression, one must explicitly acknowledge that the term itself captures a very heterogeneous group of experiences, at least some of which can be addressed by “talking” with friends, while at other times, one may need a health professional. A major challenge to acknowledging this fundamental diversity of the experiences of depression is the current approach to the classification of the condition, which is, inadvertently, contributing to the large “treatment gaps” and the clash of ideas .
The classification of depression
The past two decades have witnessed the production of a large evidence base from diverse disciplinary perspectives on the human experience that psychiatry classifies as depression. The fundamental problem with this diagnosis is that, in mimicking the model used for classifying other health conditions, a binary classification has been imposed on the continuum of mood to distinguish “cases” from “noncases.” This binary model is unsuitable for depression because there is no clear defining line which discriminates between the miseries of daily life from the “disorder” that can benefit from a clinical intervention. While the hunt for a biomarker to enable the accurate discrimination of those individuals who may require clinical interventions continues apace, there are no promising leads on the horizon. Further, given there is no obvious point in the distribution of symptoms of depression that demarcates the “well” from the “ill,” it is highly unlikely that we will ever find such a biomarker that can neatly distinguish those who are “depressed” from the rest of the population. Thus, the current approach, constrained by binary models of defining when a person may have a disorder, must be content with relying entirely on eliciting symptoms related to the inner emotional worlds of a person (the hallmark ones being feeling miserable, losing interest in things, and feeling profoundly fatigued), assessing the duration and impact of these symptoms, and, based on an arbitrary algorithm, using this information to arrive at a “diagnosis.” Critiques of the binary approach have pointed out that it risks medicalizing normative human responses to adversity and loss (a “category fallacy”) and that applying a binary categorization to a phenomenon that is so obviously continuously distributed in the population is fundamentally unsound . A dimensional approach, consistent with that proposed by the National Institute for Mental Health’s Research Domain Operating Criteria , is proposed as a more valid alternative. However, while dimensions are useful for social and neuroscientists, categories have the greatest utility for health workers and policy makers. Thinking dimensionally helps one understand problems, whereas acting categorically helps one solve them. Both matter to people who are experiencing depressive symptoms. One potential way forwards to find a balance between these two poles is by modifying the binary model into an ordinal one, a hybrid equivalent of the Likert scale, from wellness through distress and disorder of increasing severity or chronicity (Table 1).
A staged model of depression
A hybrid model is consistent with the “staging” of psychiatric disorders, advocated for more than a decade , in response to the concerns that binary diagnoses mask the heterogeneity of presentations and trajectories within each diagnostic category, and the consequent “one size fits all” approach leads to under- or overtreatment of a significant proportion of individuals with the diagnosis. Indeed, one of the key merits of staging is its direct relevance to the selection of appropriate interventions (Table 1). In the recent trial of the Healthy Activity Program (HAP), a brief psychological treatment based on behavioural activation for severe depression in primary care in India, up to 90% of individuals with depressive symptoms meeting binary criteria for a diagnosis had mild to moderate severity . The staging approach would recategorize these individuals as having a distress syndrome (typically, a mixture of mood, anxiety, and somatic symptoms). The majority of these individuals would do just as well with low-intensity interventions such as self-care, web-based psychological therapy, and social support as with clinical interventions ; indeed, baseline severity is the most consistent moderator of the effectiveness of clinical interventions, which are mostly effective for the severe forms of depression [10,11].
The role of the health care system would be to triage people who are distressed to receive low-intensity interventions in the community. This may be considered “preemptive” care, contributing not only to improved population mental health and reduced incidence of disorders but also enabling the clinical sector to attend to those with severe disorders. This approach also serves to enhance the central role of the affected person in the recovery process, empowered with adequate knowledge and support. It is important to emphasize that people who are distressed are not to be dismissed as the “worried well,” for this group contributes, from a public health perspective, to a significant fraction of the burden of impairment associated with depressive symptoms, and a proportion of these individuals may progress to develop a frank depressive episode or fail to respond to low-intensity interventions ; these will need to “graduate” to the next stage requiring clinical interventions. The point is to emphasize is that the majority of distressed individuals do not need a biomedical label and their intervention need not be medicalized.
At the next stage of this distribution, those who have severe symptoms that would be considered to meet the criteria for disorders (about 10% of the total burden of depressive symptoms in primary care in the HAP trial), there is no ambiguity in the evidence that clinical interventions are cost-effective, and the emphasis must be to scale up these interventions. While many health care systems and medical practitioners, particularly in low- and middle-income countries, have interpreted clinical interventions as being equivalent to antidepressant medication, in fact the strongest evidence from the global context is for brief psychological treatments. These treatments, largely based on cognitive—behavioural and interpersonal theoretical frameworks, are typically delivered by nonprofessional frontline workers (such as community health workers) in primary care or community-based settings in six to ten sessions over two to three months. A large body of evidence—including 27 trials in a recent review  and bolstered by several more recent trials [8,14]—testifies to the high levels of acceptability, large effects, and good value for money that these interventions offer. The scaling up of these treatments through routine primary care or other health care platforms (notably maternal health care, for which an equally impressive body of evidence demonstrates the effectiveness of nonspecialist-delivered psychological treatments ) should now focus on integrating the management of depressive disorder with other common mental disorders (anxiety disorders and somatoform disorders) through transdiagnostic interventions  and, more broadly, with other chronic conditions.
The final, most severe stage is when the depressive disorder does not respond to clinical interventions in primary care or runs a recurrent or relapsing course (approximately a third of individuals with depression in the HAP trial or in the large United States Sequenced Treatment Alternatives to Relieve Depression [STAR*D] trial, which evaluated a sequence of clinical interventions ). This group of patients who may be referred to as “chronic” or “refractory” and comprise a relatively small number of patients (under 5% of patients in primary care with any depressive symptoms in the HAP trial) are the most impaired functionally and should be the focus of specialist clinical interventions such as intensive psychosocial treatments, augmented pharmacotherapy, or ECT (the latter being especially indicated for patients with psychotic features, with severe self-neglect or very high risk of self-harm) .
A pragmatic care system for depression
A key barrier to implementing this staged model and integration of the management of a depressive episode in routine health care is the very low rates of detection of these disorders. The traditional approach to improve detection has been through training of primary care workers, despite decades of frontline experience showing that this approach has little sustainable effect. Recent randomized controlled trials in low- and middle-income countries further confirm the limited value of training alone [18,19]. While the low detection rates are likely to be the result of multiple factors, including the lack of skills or resources to respond to a diagnosis and the fear of being overwhelmed by more work, we must recognize that training alone is an inadequate intervention for improving detection. An alternative may be to incorporate screening of adults in primary care and maternal health care platforms using locally validated symptom measures such as the Patient Health Questionnaire-9 (PHQ-9), as has been recommended by the US Task Force on prevention . These measures are brief, acceptable to patients, and their scalability can be enhanced by delivery in graded steps (e.g., asking two “core” questions of the PHQ-9 to all patients and the remainder only to those who respond positively to at least one) or digitally (e.g., through apps while the patient is waiting to see the health worker). Moreover, these tools can also be used to track clinical progress (including remotely through smartphone apps) and for remote supervision of frontline workers, as has been done with high levels of acceptability in the United Kingdom’s Improving Access to Psychological Treatments program . However, screening must always be seen as only the first step of a comprehensive depression care program, for screening alone without any strategies to ensure appropriate response to the results may have limited impact on patient outcomes . Further, the cost-effectiveness of screening may be undermined by false positives , although this limitation may be mitigated by the staging approach.
Following detection, and after triaging out distressed persons to low-intensity interventions, those with a depressive episode should be offered either brief psychological treatments or antidepressant medication, both of which should be made available in routine care. The former could be delivered by the same health worker who acts as a care manager, the critical human resource needed to coordinate the collaborative care, which is the most proven delivery model for integrating depression management in routine care . Notably, amongst the effective psychological treatments for depression is behavioural activation, an approach which has conceptual alignment with activity-promotion interventions typically advocated for other common chronic conditions such as diabetes, indicating the potential synergies inherent in integrating care for these diverse conditions, in addition to the well-established rationale of the high prevalence of multiple morbidities and the bidirectional causal pathways between these morbidities . Another key shared feature of care of diverse chronic conditions is the need for a stepped care paradigm with proactive tracking of patient outcomes to identify nonresponders or relapses early and to “step up” (e.g., in the case of depression, through combined drug—psychotherapy protocols or referral of relapsing and/or refractory episodes for specialist interventions ).
Reducing the global burden of depression
Reorienting the binary diagnostic model currently in use towards a more nuanced hybrid categorical-dimensional staged model can address several barriers facing global mental health. The first is reducing the potential numbers of people who need clinical interventions. Given that the population point prevalence of depression, based on the binary system, is estimated at about 5% of the adult population —translating to over 200 million people globally—few countries, particularly in the global south, have a health care system that can cope with the massive numbers of people who would meet the current diagnostic criteria. The staged model would dramatically reduce the estimates of the numbers of persons with depressive symptoms who need clinical interventions, offering a better prospect of reducing the treatment gap for disorders both by reducing the denominator of this fraction and by focusing the energies of the health care system to detect and treat these disorders.
Second, a staged model can contribute to greater attention to prevention across the continuum of promotion, prevention, treatment, and rehabilitation. The opportunities and evidence base for prevention have mostly been focused on indicated prevention—i.e., interventions targeted at individuals who are distressed (also referred to in the binary classificatory system as persons with “subthreshold” symptoms), which are typically low-intensity versions of cognitive—behavioural interventions . This is not surprising, as it is rarely feasible to mount the kind of long-term studies needed to demonstrate the impact of interventions addressing distal social determinants, such as those aiming to promote nurturing environments (e.g., through universal early child stimulation and selective prevention for children facing social deprivation) on reducing the incidence of depression. However, it is highly likely, given the strong observational evidence linking social determinants such as childhood adversity and low educational attainment with the risk of depression in adulthood , that interventions targeting early life course influences are likely to have significant impacts on the primary prevention of depression. In the more distal life course phases of youth, building emotional and social competencies and enabling nurturing school and community environments also have a growing evidence base to support their role in prevention . The goal of these interventions is to ensure that most of the population remains in the well-being stage.
Thirdly, such a shift may enable us to “talk” more openly about depression, as it addresses fear in the community that such talk automatically implies a disorder demanding clinical interventions from a mental health specialist. Indeed, it can help reduce the yawning credibility gap—i.e., the gap between the improbably large numbers thrown up by epidemiological surveys that define “cases” based on current binary classifications and the views and concepts held by most other audiences, including the community at large and primary care practitioners (who, often with good reason, are reluctant to deploy clinical interventions to such large numbers of patients whose depressive symptoms may be interpreted as being normative or transient) . A key lesson from programs seeking to enhance access to care and the acceptability of psychological treatments for depression in the global context is that most innovators avoid psychiatric labels in favour of contextually informed metaphors and explanations . Idioms such as “thinking too much” in many African cultures and “tension” in India are less stigmatizing and widely understood, and they seamlessly capture the continuum of distress and disorder. Such approaches, which are aligned with the idiom of distress, can lead to a dramatic increase in demand for care, an essential prerequisite to ensuring that people move from more severe stages to milder ones and ultimately towards wellbeing .
“Let’s talk” sensibly
It is becoming increasingly commonplace, even trendy perhaps, to talk about depression, not least due to the growing number of celebrities, from Bruce Springsteen to Deepika Padukone, disclosing their personal experiences of struggle and recovery. However, to move this discourse beyond celebrities to the general population, in particular amongst those experiencing social adversities who are disproportionately affected by depressive symptoms, we need to move from a binary classification to a staged model that explicitly recognizes the dimensional nature of this condition. Such a revised framing has potential utility for diverse audiences, including scientists, policy makers, patients, and practitioners, and offers a framework for consensus between diverse disciplines, between the clinical and public health communities, and between professionals and civil society on how to talk sensibly about depression, in one voice. There is no doubt whatsoever that we must talk about depression more openly, but we must ensure that people experiencing depressive symptoms are always at the heart of the discourse.
The author acknowledges the comments from Steven Hollon, Pim Cuijpers, Aartjan Beekman, and Patrick MacGorry on earlier drafts of this essay.
- 1. Patel V, Chisholm D, Parikh R, Charlson FJ, Degenhardt L, et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. Lancet 2016;387: 1672–1685. pmid:26454360
- 2. Patel V, Xiao S, Chen H, Hanna F, Jotheeswaran AT, et al. The magnitude of and health system responses to the mental health treatment gap in adults in India and China. Lancet 2017;388: 3074–3084.
- 3. Summerfield D. Afterword: Against "global mental health". Transcult Psychiatry 2012;49: 519–530. pmid:23008353
- 4. Jacob KS, Patel V Classification of mental disorders: a global mental health perspective. Lancet 2014;383: 1433–1435. pmid:24759250
- 5. Kleinman A. Anthropology and Psychiatry: the role of culture in cross-cultural research on illness. British Journal of Psychiatry 1987;151: 447–454. pmid:3447661
- 6. Cuthbert B, Insel TR Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med 2013: 11:126. pmid:23672542
- 7. McGorry P, Keshavan M, Goldstone S, Amminger P, Allott K, et al. Biomarkers and clinical staging in psychiatry. World Psychiatry 2014;13: 211–223. pmid:25273285
- 8. Patel V, Weobong B, Weiss HA, Anand A, Bhat B, et al. The Healthy Activity Program (HAP), a lay counsellor-delivered brief psychological treatment for severe depression, in primary care in India: a randomised controlled trial. Lancet 2017;389: 176–185. pmid:27988143
- 9. Karyotaki E, Riper H, Twisk J, Hoogendoorn A, Kleiboer A, et al. Efficacy of self-guided internet-based cognitive behavioral therapy (iCBT) in treatment of depressive symptoms: An individual participant data meta-analysis. JAMA Psychiatry. 2017. In press.
- 10. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303: 47–53. pmid:20051569
- 11. Driessen E, Cuijpers P, Hollon SD, Dekker JJ. Does pretreatment severity moderate the efficacy of psychological treatment of adult outpatient depression? A meta-analysis. J Consult Clin Psychol 2010;78: 668–680. pmid:20873902
- 12. Judd LL, Akiskal HS, Zeller PJ, Paulus M, Leon AC, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 2000;57: 375–380. pmid:10768699
- 13. Singla DR, Kohrt BA, Murray LK, Anand A, Chorpita BC, et al. Psychological treatments for the world: Lessons from low- and middle-income countries. Annual Review of Clinical Psychology 2017. In press.
- 14. Chibanda D, Weiss HA, Verhey R, et al. Effect of a primary care—based psychological intervention on symptoms of common mental disorders in zimbabwe: A randomized clinical trial. JAMA 2016;316: 2618–2626. pmid:28027368
- 15. Rahman A, Fisher J, Bower P, Luchters S, Tran T, et al. Interventions for common perinatal mental disorders in women in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ 2013;91: 593–601I. pmid:23940407
- 16. Bolton P, Lee C, Haroz EE, Murray L, Dorsey S, et al. A transdiagnostic community-based mental health treatment for comorbid disorders: development and outcomes of a randomized controlled trial among Burmese refugees in Thailand. PLoS Med 2014;11: e1001757. pmid:25386945
- 17. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163: 1905–1917. pmid:17074942
- 18. Fairall LR, Folb N, Timmerman V, Lombard C, Steyn K, et al. Educational Outreach with an Integrated Clinical Tool for Nurse-Led Non-communicable Chronic Disease Management in Primary Care in South Africa: A Pragmatic Cluster Randomised Controlled Trial. PLoS Medicine 2016;13: e1002178. pmid:27875542
- 19. Kauye F, Jenkins R, Rahman A. Training primary health care workers in mental health and its impact on diagnoses of common mental disorders in primary care of a developing country, Malawi: a cluster-randomized controlled trial. Psychol Med 2014;44:657–66. pmid:23721658
- 20. Reynolds C, Patel V. Screening for depression: the global mental health context. World Psychiatry 2017. In press.
- 21. Clark DM, Layard R, Smithies R, Richards DA, Suckling R, et al. Improving access to psychological therapy: Initial evaluation of two UK demonstration sites. Behav Res Ther 2009;47: 910–920. pmid:19647230
- 22. Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136: 765–776. pmid:12020146
- 23. Paulden M, Palmer S, Hewitt C, Gilbody S. Screening for postnatal depression in primary care: cost effectiveness analysis. BMJ 2009;339: b5203. pmid:20028779
- 24. Archer J, Bower P, Gilbody S, Lovell K, Richards D, et al. Collaborative care for depression and anxiety problems. Cochrane Database Syst Rev 2012;10: CD006525. pmid:23076925
- 25. Patel V, Chatterji S. Integrating Mental Health In Care For Noncommunicable Diseases: An Imperative For Person-Centered Care. Health Aff (Millwood) 2015;34: 1498–1505.
- 26. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10: e1001547. pmid:24223526
- 27. van Zoonen K, Buntrock C, Ebert DD, Smit F, Reynolds CF 3rd, et al. Preventing the onset of major depressive disorder: a meta-analytic review of psychological interventions. Int J Epidemiol 2014;43: 318–329. pmid:24760873
- 28. Lund C, De Silva M, Plagerson S, Cooper S, Chisholm D, et al. Poverty and mental disorders: breaking the cycle in low-income and middle-income countries. Lancet 2011;2011: 1–13.
- 29. Patel V. Rethinking mental health care: bridging the credibility gap. Intervention 2014;12: 15–20.
- 30. Patel V, Chowdhary N, Rahman A, Verdeli H. Improving access to psychological treatments: Lessons from developing countries. Behav Res Ther 2011;49: 523–528. pmid:21788012
- 31. Shidhaye R, Murhar V, Gangale S, Aldridge L, Shastri R, et al. The effect of VISHRAM, a grass-roots community-based mental health programme, on the treatment gap for depression in rural communities in India: a population-based study. Lancet Psychiatry 2017;4: 128–135. pmid:28063879
- Depression is the leading mental health—related cause of the global burden of disease and is the focus of World Health Day 2017.
- Despite robust evidence of the effectiveness of interventions ranging from self-care to clinical interventions, the vast majority of people with depressive symptoms do not receive any care.
- The majority of persons meeting the binary diagnostic criteria for depression have mild to moderate symptoms that most often do not need clinical interventions.
- A staged model, from wellness to distress to disorder, offers a hybrid between binary and dimensional approaches to classifying depressive symptoms, with specific interventions delivered through distinct delivery platforms addressing each stage.
- Such a staged approach is likely to be more efficient and acceptable to diverse audiences (from the general population to policy makers and practitioners) and provides the basis for these audiences to talk with one voice about this condition.